InfiCure Bio AB

InfiCure Bio focus on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.

Approximately 40 percent of deaths in the industrial world is caused by fibrosis of the heart, liver, lungs and kidneys. Despite the high prevalence of fibrosis and its enormous impact on human health, there are currently no approved agents that can prevent, arrest, or reverse fibrosis.

InfiCure Bio offers advanced drug validation services for pharmaceutical companies developing drugs against fibroris - or scar tissue formation in organs.


Contact details
Tvistevägen 48C, 907 36Umeå
Phone: 46(0)70-366 4666